A preclinical study of a novel dual-modality contrast agent in rodent models
Compared to Gadavist® and ICG, PL002 provided sustained support for MRI and FI of GBM for 72 h, with a broad therapeutic window. This dual-modality contrast agent holds significant potential and promise for applications in preoperative assessment of resection margins, real-time intraoperative guidance, and postoperative verification of the extent of resection.
Authors
- Yuxin Han (ORCID: https://orcid.org/0009-0004-6045-3367)
- Xiaoxin Zhou (ORCID: https://orcid.org/0000-0002-1058-6418)
- Si-Ying Yang
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2025-03-20
- DOI
- https://doi.org/10.3389/fbioe.2025.1557772
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00